Ziad Bakouny, MD, MSc (@ziadbakouny) 's Twitter Profile
Ziad Bakouny, MD, MSc

@ziadbakouny

PGY-4 Heme/Onc @MSK_DeptOfMed | via @USJLiban @DanaFarber @BrighamMedRes | @ASCO #IMG CoP & #JCOCCI Assoc Editor | Cancer Genomics | FCOI: bit.ly/3abof8w

ID: 481507046

linkhttps://scholar.google.com/citations?user=cSTV2eUAAAAJ&hl=en calendar_today02-02-2012 21:03:26

7,7K Tweet

3,3K Followers

1,1K Following

Ziad Bakouny, MD, MSc (@ziadbakouny) 's Twitter Profile Photo
Ziad Bakouny, MD, MSc
@ziadbakouny

a year ago

Dr. Robert Motzer MD with an important presentation of #CHECKMATE914 Part A subgroup analyses. ASCO #ASCO23 While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit

Dr. <a href="/motzermd/">Robert Motzer MD</a> with an important presentation of #CHECKMATE914 Part A subgroup analyses. <a href="/ASCO/">ASCO</a> #ASCO23 While the overall trial showed no improved outcomes with the combination of Nivo/Ipi vs placebo, sarcomatoid, high grade, and PD-L1 positive patients seemed to derive benefit